



DexTech

Know-how in Translational Research

Press release 2025-02-25

DexTech Medical AB, 556664-6203

DexTech Medical is funded through Q4, 2026

Regarding the ongoing Phase 1 study investigating the *efficacy of OsteoDex* in patients with *progressive* treatment-resistant multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The study is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed treatment-resistant disease, who received 1–5 prior lines of therapy. *The primary objective is to confirm safety and tolerability and with a secondary objective to determine indications of treatment response.* The number of patients to be included in the study will now be a maximum of 12 (previously a maximum of 20). *Primary and secondary objectives can be achieved* despite lower patient numbers and are an adaptation to available patients that can be recruited.

Through reduced costs, the company can announce that operations are financed until Q4, 2026.

For more information about DexTech, please contact:

Gösta Lundgren – CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on February 25, 2025.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The lead candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech's goal is to out-license each drug candidate no later than after completion of the phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.